Diagnosis and Care of Infants and Children with Pompe Disease

  • Andreas Hahn
  • Julia B Hennermann
  • Martina Huemer
  • Christoph Kampmann
  • Thorsten Marquardt
  • Eugen Mengel
  • Wolfgang Müller-Felber
  • Nicole Maria Muschol
  • Marianne Rohrbach
  • Florian Stehling

Related Research units

Abstract

Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced enzyme activity results in abnormal intra- and extralysosomal glycogen deposition as well as impaired cellular function and autophagy. Age at manifestation and severity of disease depend on residual enzyme activity. Enzyme replacement therapy (ERT) is available since 2006. In infantile onset Pompe disease, the most severe form, markedly prolonged survival has resulted in a new phenotype with symptoms and problems not encountered previously. In addition, it became apparent that antibody formation against the recombinant human enzyme may adversely affect the response to ERT. This review summarizes new knowledge gained in the last years concerning care of pediatric patients with Pompe disease and gives recommendations for diagnostics, treatment, and follow-up.

Bibliographical data

Translated title of the contributionDiagnostik und Therapie des Morbus Pompe im Kindesalter
Original languageEnglish
ISSN0300-8630
DOIs
Publication statusPublished - 18.02.2020

Comment Deanary

© © Georg Thieme Verlag KG Stuttgart · New York.

PubMed 32069498